Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.46 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.46 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.38 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.35 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | USP2 | O75604 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207948 | 0.98 | SIGMAR1 (0.47) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL6830556 | 0.79 | ADRB1 (0.46) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL7757790 | 0.77 | ADRB1 (0.57) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL746788 | 0.76 | ADRB1 (0.47) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL7582179 | 0.76 | ADRB1 (0.47) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL746085 | 0.76 | SIGMAR1 (0.47) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL1442618 | 0.76 | SIGMAR1 (0.47) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL9772057 | 0.75 | SIGMAR1 (0.46) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL8797791 | 0.74 | ADRB1 (0.44) | SIGMAR1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL6012283 | 0.74 | USP2 (0.49) | SIGMAR1ADRB1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111320594-A | Carilazine impurity and preparation process and application thereof | 江苏恩华药业股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-108299337-A | The preparation method of one kind 2,3- dichlorophenylpiperazine hydrochlorides | 吴江信凯医药科技有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-108069900-A | The preparation method and purposes of Aripiprazole hydrochloride | 齐鲁制药有限公司 | 2018-05-25 | — | — | CN | disclosed |
| CN-104059046-A | Flavonoid derivative and application thereof | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2014-09-24 | — | — | CN | disclosed |
| EP-1845088-B1 | An improved process for the preparation of aripipirazole | RANBAXY LAB LTD (IN) | 2009-07-22 | — | — | EP | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1845088-A1 | An improved process for the preparation of aripipirazole | Ranbaxy Laboratories Limited (IN) | 2007-10-17 | — | — | EP | disclosed |
| US-20070238876-A1 | PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238876-A1 | PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE | CYP2F1, CYP2C19, CYP2A6 | SIGMAR1 1420/4885ADRB1 1893/4885HTR3E 1045/4885 |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | SIGMAR1 2939/4885ADRB1 404/4885HTR3E 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.